A new study demonstrates that CAR regulatory T cells targeting oxidized LDL can cut atherosclerotic plaque by 70% in mice, offering a potential one-time therapy for cardiovascular disease prevention. ...
Eli Lilly’s AI collaborations via TuneLab cut preclinical timelines by up to 30% and reduce attrition rates, democratizing drug discovery for smaller firms with enhanced data privacy. Eli Lilly&...
Artificial intelligence is accelerating drug discovery for rare diseases, reducing costs by up to 50% and shortening timelines, enabling bespoke therapies and improving healthcare equity globally. AI ...
A recent pilot study explores the safety and efficacy of intravenous BPC-157 in humans, showing potential for muscle and tendon repair with minimal side effects. A groundbreaking pilot study on intrav...
A pilot study confirms the safety of intravenous BPC-157 in humans, with potential applications in sports medicine and rehabilitation. New human data suggests intravenous BPC-157 may be safe, opening ...
A recent pilot study highlights the safety of intravenous BPC-157 in humans, reinforcing its potential for treating musculoskeletal injuries and accelerating tissue repair. New research validates the ...
